Literature DB >> 6609208

Specific antibody synthesis in vitro. I. Technical considerations.

A L Moore, W B Ershler, M P Hacker.   

Abstract

Previously described methods for measuring specific antibody production in vitro are complex and frequently require the addition of a non-specific mitogen and 2 or more separate steps including a lymphocyte culture and then an antibody assay. In this report we present further details regarding a 1-step, non-mitogen requiring assay for specific antibody synthesis combining microculture and enzyme-linked immunoassay techniques. Peripheral blood mononuclear cells from recently immunized subjects are cultured in antigen-coated plastic wells and the specific antibody produced and adhered to the solid-phase antigen is measured in an enzyme-linked immunoassay. The production of specific antibody in vitro did not occur in lymphocyte preparations that were frozen, thawed and incubated, nor did it occur in cultures containing puromycin. T cell separation and remixture experiments indicated that T cells provide significant augmentation under the conditions of this assay. It is apparent that the antibody measured was synthesized in vitro and that cell-cell interactions are operant. The assay may prove useful in the assessment of immune competence and in determining in vitro the effect of certain biologic response modifiers on antibody production.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6609208     DOI: 10.1016/0022-1759(84)90384-3

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  2 in total

1.  Influenza and aging: age-related changes and the effects of thymosin on the antibody response to influenza vaccine.

Authors:  W B Ershler; A L Moore; M A Socinski
Journal:  J Clin Immunol       Date:  1984-11       Impact factor: 8.317

2.  Specific antibody synthesis in vitro. IV. The correlation of in vitro and in vivo antibody response to influenza vaccine in rhesus monkeys.

Authors:  W B Ershler; C L Coe; S Gravenstein; K T Schultz; R G Klopp
Journal:  Clin Exp Immunol       Date:  1988-09       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.